University of Washington
Seattle, Washington, 98195, United States
Location status: Recruiting
Location contact
Chet T. Moritz, PhD
PRINCIPAL_INVESTIGATOR
Fatma Inanici, MD, Ph.D.
CONTACT
Fatma Inanici, MD, PhD
SUB_INVESTIGATOR
NCT Number: NCT05267951
The purpose of this study is to assess the efficacy of non-invasive (transcutaneous) closed-loop electrical spinal cord stimulation for recovery of upper limb function (Aim 1) and spasticity (Aim 2) following spinal cord injury.
Interested in participating?
Request Info21 year–70 year
All sexes
Interventional
Not applicable
Seattle, Washington, 98195, United States
Location status: Recruiting
Chet T. Moritz, PhD
PRINCIPAL_INVESTIGATOR
Fatma Inanici, MD, Ph.D.
CONTACT
Fatma Inanici, MD, PhD
SUB_INVESTIGATOR
After being informed about the purpose, study timeline, and procedures, all participants giving written informed consent will undergo repeated baseline measurements throughout four weeks, followed by intensive exercise therapy for six weeks.
Next, participants will receive (1) closed-loop stimulation and (2) open-loop stimulation treatment for Aim 1 Section of the study. Stimulation will be delivered non-invasively using skin electrodes on the back of the neck. Each treatment arm will last six weeks. The investigators will determine the order of the treatment arms randomly. For closed-loop stimulation, The investigators will place a sensor on the arm muscles over the skin. This sensor will detect the movement and start the stimulation accordingly.
For Aim 2 Section, intervention arms will consist of (1) transcutaneous stimulation, followed by (2) spasticity-reducing stimulation treatment arms.
There will be a 6-week waiting period between two stimulation arms where participants will not receive any stimulation or exercise therapy. Treatments will last 90 minutes per session, three sessions per week. Overall participation in the study will last ten months: Four weeks baseline + three treatment periods (each will last six weeks) + six weeks waiting period between stimulation treatments + 12 weeks follow-up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.
Exercise therapy consists of repeated functional hand and arm movements
Other names: Intensive exercise therapy
Time frame: "Repeated measurements once every two weeks throughout the study, an average of 10 months".
Measurement of upper limb strength, sensation, qualitative prehension, and quantitative prehension (range 0-188, higher score mean better outcome)
Time frame: "Repeated measurements once every two weeks throughout the study, an average of 10 months".
Measures unilateral and bilateral hand and arm function (range 0-128, higher score mean better outcome)
Time frame: "Repeated measurements once every two weeks throughout the study, an average of 10 months".
Grip and pinch force measurement using a dynamometer (higher score mean better outcome)
Time frame: "Repeated measurements once every two weeks throughout the study, an average of 10 months".
Clinician administered assessment of spasticity (range 0-4, lower score mean better outcome)
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Standard manual muscle strength examination (Range 0-100 points, higher score mean better outcome)
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Standard examination of dermatomal sensation (range 0-224 points, higher score mean better outcome)
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Clinician assessment to document remaining autonomic functions after spinal cord injury
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Electrophysiologic measurement of H-reflex (lower Hmax/Mmax ratio mean better outcome)
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Electrophysiologic evaluation of sensory pathways between the brain and the limb (shorter latency mean better outcome)
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Electrophysiologic evaluation of motor pathways between the brain and the muscles (higher amplitude mean better outcome)
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Quantification of the level of independence in daily activities (range 0-100 points, higher score mean better outcome)
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Self-reported questionnaire on quality of life (range 0-100 points, higher score mean better outcome)
Time frame: "Baseline"/"At the end of each treatment arm"/"Through study completion"
Patient-reported questionnaire (range 0-100 points, higher score mean better outcome)
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Patient-reported questionnaire (range 0-47 points, lower score mean better outcome)
Time frame: "Repeated measurements once every eight weeks throughout the study, an average of 10 months".
Patient-reported questionnaire (range 0-164 points, lower score mean better outcome)
Contact information is provided by the study sponsor or research team.
University of Washington
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04144972
Autonomic Nervous System Diseases, Central Nervous System Diseases
San Francisco, California, United States
View Trial DetailsNCT06455137
Central Nervous System Diseases, Nervous System Diseases
Hualien City, Taiwan
View Trial DetailsNCT06438471
Bone Diseases, Central Nervous System Diseases
Augusta, Georgia, United States
View Trial DetailsNCT00623389
Brain Diseases, Cardiovascular Diseases
Cleveland, Ohio, United States
View Trial Details